NCT03181633View on ClinicalTrials.gov

A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 22, 2017

Primary Completion Date

January 4, 2022

Study Completion Date

January 4, 2022

Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
DRUG

ACH-0144471

ACH-0144471 will be administered to all participants enrolled in the study.

Trial Locations (4)

Unknown

Clinical Trial Site, Avellino

Clinical Trial Site, Naples

Clinical Trial Site, Auckland

Clinical Trial Site, Seoul

Sponsors
All Listed Sponsors
collaborator

Achillion, a wholly owned subsidiary of Alexion

INDUSTRY

lead

Alexion Pharmaceuticals, Inc.

INDUSTRY